ClinicalTrials.gg
CompletedNCT06816251Updated Aug 24, 2026

A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy

A Phase 2 interventional study of HRS-1893 and HRS-1893 placebo in Non-obstructive Hypertrophic Cardiomyopathy, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Cardiomyopathy, Hypertrophic with a site in China — 30 open to participants now, 43 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · China.

Enrollment
20th of 39
84 · median 84
Started
2025
with 10 others
Phase 2
4 of 71
2 open now
Registered
54th of 71
by date
Lead sponsor
7 of 71
Shandong Suncadia Medicine Co., Ltd.

Among the 71 studies in Cardiomyopathy, Hypertrophic with a site in China, this one is the 20th largest by enrollment of the 39 interventional ones that give a count, is one of 11 that started in 2025, is one of 4 in phase 2, and was the 54th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

30 of the 71 studies in Cardiomyopathy, Hypertrophic with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Cardiomyopathy, Hypertrophic with a site in China, or all of them as a file.
02

Study summary

This study mainly evaluated the safety and tolerability of HRS-1893 in subjects with non-obstructive hypertrophic cardiomyopathy, and the efficacy and plasma concentrations of different dosing regimens in subjects with non-obstructive hypertrophic cardiomyopathy.

03

Conditions studied

  • Non-obstructive Hypertrophic Cardiomyopathy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18\~85 years old (including boundary value), male or female.
  2. \< 35 kg/m2.
  3. Understand the study procedures and methods, voluntarily participate in this trial, and sign the form in writing.
  4. Female subjects of must have a serum pregnancy test prior to the first dose with a negative result and must be non-lactating during the study.
  5. Female subjects of childbearing potential and male subjects whose partners are women of childbearing potential must agree to refrain from donating sperm/eggs from the time of signing the informed consent form until 3 months after the last dose of the trial drug, and comply with the relevant requirements.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected infiltration, hereditary, or storage disorder that can cause myocardial hypertrophy.
  2. Paroxysmal atrial flutter or atrial fibrillation with clinical symptoms at screening.
  3. History of syncope or sustained ventricular tachycardia within 6 months prior to screening.
  4. Those who have participated in the clinical trial of any drug or medical device within 3 months before screening.
  5. Other conditions that the investigator considers the subject to be unsuitable for participating in this trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    HRS-1893 low-dose group

    Drug: HRS-1893

  • Placebo comparator
    HRS-1893 placebo low-dose group

    Drug: HRS-1893 placebo

  • Experimental
    HRS-1893 high-dose group

    Drug: HRS-1893

  • Placebo comparator
    HRS-1893 placebo high-dose group

    Drug: HRS-1893 placebo

Interventions

  • HRS-1893 tablet.

  • DrugHRS-1893 placebo

    HRS-1893 tablet placebo.

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Time frame: Up to 14 weeks.

  2. The incidence of left ventricular ejection fraction (LVEF) < 50%

    Time frame: Up to 14 weeks.

Secondary outcomes

  1. Peak oxygen uptake (pVO2) value

    Time frame: About 12 weeks.

  2. The cardiac troponin value

    Time frame: About 12 weeks.

07

Study locations

1 site
  • Fuwai Hospital
    Beijing, Beijing Municipality 100032, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Nov 2025, 8 months.

Of 20 phase 2 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2025
First posted
Feb 10, 2025
StartActual
Feb 25, 2025
Primary completionActual
Nov 18, 2025
CompletionActual
Nov 18, 2025
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06816251
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Feb 25, 2025
Primary completion
Nov 18, 2025
Completion
Nov 18, 2025
Last update
Aug 24, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-1893

Start the discussion